Target- |
Mechanism Cell replacements |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism NPRA agonists [+1] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date22 Jun 2022 |
Sponsor / Collaborator |
Start Date15 Nov 2020 |
Sponsor / Collaborator |
Start Date20 Jul 2020 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Deramiocel | Myocardial Infarction More | Discontinued |
Cenderitide ( NPRA x NPRB ) | Chronic heart failure More | Pending |